Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

BCMA-targeted immunotherapy for multiple myeloma
Bo Yu, Tianbo Jiang, Delong Liu
Journal of Hematology & Oncology (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 160

Showing 1-25 of 160 citing articles:

Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies
Tian Zheng, Ming Liu, Ya Zhang, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 190
Targeting Akt in cancer for precision therapy
Hui Hua, Hongying Zhang, Jingzhu Chen, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 162
Cell Therapy: Types, Regulation, and Clinical Benefits
Abed El-Hakim El-Kadiry, Moutih Rafei, Riam Shammaa
Frontiers in Medicine (2021) Vol. 8
Open Access | Times Cited: 159
Nano-Based Approved Pharmaceuticals for Cancer Treatment: Present and Future Challenges
Francisco Rodríguez, Pablo Caruana, Noa De la Fuente, et al.
Biomolecules (2022) Vol. 12, Iss. 6, pp. 784-784
Open Access | Times Cited: 155
Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents
Adam D. Cohen, María‐Victoria Mateos, Yaël Cohen, et al.
Blood (2022) Vol. 141, Iss. 3, pp. 219-230
Open Access | Times Cited: 130
Nanobody-based CAR-T cells for cancer immunotherapy
Pouya Safarzadeh Kozani, Abdolhossein Naseri, Seyed Mohamad Javad Mirarefin, et al.
Biomarker Research (2022) Vol. 10, Iss. 1
Open Access | Times Cited: 102
A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma
Anita D’Souza, Nina Shah, Cesar Rodriguez, et al.
Journal of Clinical Oncology (2022) Vol. 40, Iss. 31, pp. 3576-3586
Open Access | Times Cited: 84
Development of therapeutic antibodies for the treatment of diseases
Zeng Wang, Guoqing Wang, Huaqing Lu, et al.
Molecular Biomedicine (2022) Vol. 3, Iss. 1
Open Access | Times Cited: 75
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma
Vânia Hungria, Paweł Robak, Marek Hus, et al.
New England Journal of Medicine (2024) Vol. 391, Iss. 5, pp. 393-407
Closed Access | Times Cited: 39
Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma
Gils Roex, Marijke Timmers, Kristien Wouters, et al.
Journal of Hematology & Oncology (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 132
Prognostic and predictive biomarker developments in multiple myeloma
Craig T. Wallington‐Beddoe, Rachel L. Mynott
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 91
Bispecific Antibodies in Multiple Myeloma: Present and Future
Guido Lancman, Dahniel Sastow, Hearn Jay Cho, et al.
Blood Cancer Discovery (2021) Vol. 2, Iss. 5, pp. 423-433
Open Access | Times Cited: 75
Chimeric antigen receptor- and natural killer cell receptor-engineered innate killer cells in cancer immunotherapy
Cai Zhang, Yuan Hu, Weihua Xiao, et al.
Cellular and Molecular Immunology (2021) Vol. 18, Iss. 9, pp. 2083-2100
Open Access | Times Cited: 69
Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma
Matthew J. Frigault, Michael R. Bishop, Jacalyn Rosenblatt, et al.
Blood Advances (2022) Vol. 7, Iss. 5, pp. 768-777
Open Access | Times Cited: 47
Multiple Myeloma Therapy: Emerging Trends and Challenges
Danai Dima, Dongxu Jiang, Divya Jyoti Singh, et al.
Cancers (2022) Vol. 14, Iss. 17, pp. 4082-4082
Open Access | Times Cited: 41
Single-cell analysis of anti-BCMA CAR T cell therapy in patients with central nervous system autoimmunity
Chuan Qin, Min Zhang, Dapeng Mou, et al.
Science Immunology (2024) Vol. 9, Iss. 95
Open Access | Times Cited: 13
Challenges and innovations in CAR-T cell therapy: a comprehensive analysis
Jingming Luo, Xianwen Zhang
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 12
Targets of tumor microenvironment for potential drug development
Ling Zhang, Ziruoyu Wang, Kailu Liu, et al.
MedComm – Oncology (2024) Vol. 3, Iss. 1
Open Access | Times Cited: 10
Update on B‐cell maturation antigen‐directed therapies in AL amyloidosis
Krzysztof Jamroziak, Klaudia Zielonka, Jahanzaib Khwaja, et al.
British Journal of Haematology (2025)
Closed Access | Times Cited: 1
BCMA-targeted therapies for multiple myeloma: latest updates from 2024 ASH annual meeting
Huijian Zheng, Huajian Xian, Wenjie Zhang, et al.
Journal of Hematology & Oncology (2025) Vol. 18, Iss. 1
Open Access | Times Cited: 1
Impact of Endocytosis Mechanisms for the Receptors Targeted by the Currently Approved Antibody-Drug Conjugates (ADCs)—A Necessity for Future ADC Research and Development
Manar Hammood, Andrew W.B. Craig, Jeffrey V. Leyton
Pharmaceuticals (2021) Vol. 14, Iss. 7, pp. 674-674
Open Access | Times Cited: 51
Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting
Jing-Zhou Hou, Jing Christine Ye, Jeffrey J. Pu, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 46
From Life in the Sea to the Clinic: The Marine Drugs Approved and under Clinical Trial
Emiliano Cappello, Paola Nieri
Life (2021) Vol. 11, Iss. 12, pp. 1390-1390
Open Access | Times Cited: 45
Idecabtagene Vicleucel (ide-cel) CAR T-cell Therapy for Relapsed and Refractory Multiple Myeloma
Larry D. Anderson
Future Oncology (2021) Vol. 18, Iss. 3, pp. 277-289
Closed Access | Times Cited: 44
T-cell-engaging antibodies for the treatment of solid tumors: challenges and opportunities
Patrick A. Baeuerle, Holger Wesche
Current Opinion in Oncology (2022) Vol. 34, Iss. 5, pp. 552-558
Open Access | Times Cited: 35
Page 1 - Next Page

Scroll to top